haloperidol has been researched along with n-methyl-3,4-methylenedioxyamphetamine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.64) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Glennon, RA; Higgs, R; Issa, H; Young, R | 1 |
| Fadayel, GM; Schmidt, CJ; Sullivan, CK; Taylor, VL | 1 |
| Abbate, GM; Black, CK; Schmidt, CJ; Taylor, VL | 1 |
| Chiodo, LA; Freeman, AS; Kelland, MD | 1 |
| Champney, TH; Frye, GD; Matthews, RT | 1 |
| Borne, RF; Davis, WM | 1 |
| Green, AR; Hewitt, KE | 1 |
| Atrens, DM; Christie, MJ; Jackson, DM; Lin, HQ; McGregor, IS | 1 |
| Calder, L; Clikeman, J; Finnegan, KT; Karler, R; Wei, S | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; Martín, AB; O'Shea, E | 1 |
| Liechti, ME; Vollenweider, FX | 1 |
| Geyer, MA; Hell, D; Liechti, ME; Vollenweider, FX | 1 |
| Kovar, KA; Mayerhofer, A; Meyer, A; Schmidt, WJ | 1 |
| Banjaw, MY; Mayerhofer, A; Schmidt, WJ | 1 |
| Kohles, T; Kovar, KA; Lebsanft, HB; Schmidt, WJ | 1 |
| Blessing, WW | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC | 1 |
| Aguilar, MA; Daza-Losada, M; Miñarro, J; Rodríguez-Arias, M; Roger-Sánchez, C; Vidal-Infer, A | 1 |
| Hondebrink, L; Meulenbelt, J; Rietjens, SJ; Westerink, RH | 1 |
| Edut, S; Pick, CG; Rehavi, M; Rubovitch, V; Schreiber, S | 1 |
| Fukase, M; Iwase, Y; Mochizuki, A; Mori, T; Shibasaki, M; Suzuki, T; Takahashi, Y; Uzawa, N | 1 |
1 review(s) available for haloperidol and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.
Topics: Animals; Blood Pressure; Body Temperature; Brain; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D6; Drug Interactions; Glutathione Transferase; Haloperidol; Heart Rate; Humans; Ketanserin; Models, Animal; N-Methyl-3,4-methylenedioxyamphetamine; Neurotransmitter Transport Proteins; Polymorphism, Genetic; Propanolamines; Receptors, Neurotransmitter; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2012 |
1 trial(s) available for haloperidol and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
Topics: Adult; Affect; Antipsychotic Agents; Anxiety; Blood Pressure; Body Temperature; Consciousness; Dopamine; Double-Blind Method; Drug Interactions; Hallucinogens; Haloperidol; Heart Rate; Humans; Interviews as Topic; N-Methyl-3,4-methylenedioxyamphetamine | 2000 |
20 other study(ies) available for haloperidol and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Discrimination, Psychological; Dopamine Antagonists; Generalization, Stimulus; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Serotonin Antagonists | 1992 |
5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Dialysis; Dopamine; Fluorobenzenes; Haloperidol; Homovanillic Acid; Male; N-Methyl-3,4-methylenedioxyamphetamine; Piperidines; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Antagonists | 1992 |
Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Body Temperature; Cerebral Cortex; Corpus Striatum; Haloperidol; Hippocampus; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurotoxins; Piperidines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Reference Values; Serotonin; Serotonin Antagonists | 1990 |
(+/-)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Apomorphine; Biogenic Amines; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Ergolines; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Quinpirole; Rats; Rats, Inbred Strains; Serotonin; Substantia Nigra | 1989 |
Effects of (+-)3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Behavior, Animal; Brain; Brain Chemistry; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Haloperidol; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Stereotyped Behavior; Time Factors | 1989 |
Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Haloperidol; Lethal Dose 50; Male; Mice; Mice, Inbred ICR; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Phenobarbital; Phenoxybenzamine; Propranolol | 1984 |
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
Topics: Animals; Chlormethiazole; Dizocilpine Maleate; Haloperidol; Hydroxyindoleacetic Acid; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Radioligand Assay; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin | 1994 |
Contrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Avoidance Learning; Benzazepines; Dextroamphetamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Raclopride; Rats; Rats, Wistar; Receptors, Dopamine D1; Salicylamides; Taste | 1994 |
Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Calcium Channel Blockers; Cerebral Cortex; Flunarizine; Haloperidol; Hippocampus; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Nifedipine; Rats; Rats, Sprague-Dawley; Seizures; Serotonin; Stereotyped Behavior; Verapamil | 1993 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Serotonin | 1999 |
Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.
Topics: Acoustic Stimulation; Adult; Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituation, Psychophysiologic; Haloperidol; Humans; Ketanserin; Male; Models, Psychological; N-Methyl-3,4-methylenedioxyamphetamine; Psychiatric Status Rating Scales; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Serotonin | 2001 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2002 |
Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat.
Topics: Adrenergic Uptake Inhibitors; Alkaloids; Animals; Catalepsy; Central Nervous System; Central Nervous System Stimulants; Dopamine Antagonists; Drug Administration Schedule; Haloperidol; Male; Movement; N-Methyl-3,4-methylenedioxyamphetamine; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervation; Disease Models, Animal; Gait Disorders, Neurologic; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereoisomerism | 2005 |
Clozapine increases cutaneous blood flow and reduces sympathetic cutaneous vasomotor alerting responses (SCVARs) in rats: comparison with effects of haloperidol.
Topics: Animals; Antipsychotic Agents; Arousal; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Injections, Subcutaneous; Laser-Doppler Flowmetry; Lipopolysaccharides; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Skin; Skin Temperature; Sympathetic Nervous System; Vasoconstriction; Vasomotor System | 2005 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Creatine Kinase; Dantrolene; Disseminated Intravascular Coagulation; Female; Genetic Variation; Hallucinogens; Haloperidol; Halothane; Humans; Multiple Organ Failure; N-Methyl-3,4-methylenedioxyamphetamine; Neuroleptic Malignant Syndrome; Recurrence; Rhabdomyolysis; Ryanodine Receptor Calcium Release Channel; Spectrum Analysis; Young Adult | 2012 |
Role of the dopaminergic system in the acquisition, expression and reinstatement of MDMA-induced conditioned place preference in adolescent mice.
Topics: Animals; Benzazepines; Blotting, Western; Conditioning, Operant; Dopamine; Dopamine Antagonists; Haloperidol; Male; Mice; N-Methyl-3,4-methylenedioxyamphetamine; Raclopride; Serotonin; Thiazepines | 2012 |
A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice.
Topics: Animals; Brain; Brain Concussion; Brain-Derived Neurotrophic Factor; Catecholamines; Dopaminergic Neurons; Haloperidol; Mice; Mice, Inbred ICR; N-Methyl-3,4-methylenedioxyamphetamine; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2014 |
Synergistic effects of MDMA and ethanol on behavior: Possible effects of ethanol on dopamine D
Topics: Animals; Benzazepines; Dopamine Antagonists; Ethanol; Haloperidol; Male; Mice; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Nucleus Accumbens; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2021 |